A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Etrumadenant (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Regorafenib
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ARC-9
Sponsors Arcus Biosciences

18 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Jul 2025.
18 Nov 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Jul 2025.
06 Nov 2024 According to an Arcus Biosciences media release, Biomarker data from cohort B of study is presented at SITC in November.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com